Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | USP14 | P54578 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23245332 | 1.00 | HSD11B1 (0.44) | HSD11B1POLBALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL12979859 | 1.00 | HSD11B1 (0.44) | HSD11B1POLBALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL23245334 | 1.00 | HSD11B1 (0.44) | HSD11B1POLBALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL23245581 | 0.82 | HSD11B1 (0.37) | HSD11B1POLBALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL2708054 | 0.82 | HSD11B1 (0.40) | HSD11B1POLBALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL23245578 | 0.82 | HSD11B1 (0.37) | HSD11B1POLBALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL23245582 | 0.82 | HSD11B1 (0.37) | HSD11B1POLBALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL23245444 | 0.82 | HSD11B1 (0.32) | HSD11B1POLBALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL25204662 | 0.77 | POLB (0.33) | POLBALDH1A1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL25204660 | 0.77 | POLB (0.33) | POLBALDH1A1CYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183256-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | YUMANITY THERAPEUTICS, INC. | 2023-06-15 | — | — | US | disclosed |
| US-11560385-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| EP-3814338-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | Proteostasis Therapeutics, Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20210115057-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115057-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSME3, PSMC4 | HSD11B1 2082/4885POLB 1022/4885ALDH1A1 3438/4885 |
| US-11560385-B2 | Proteasome activity enhancing compounds | PSMG3, PSME3, PSMC4 | HSD11B1 2082/4885POLB 1022/4885ALDH1A1 3438/4885 |
| US-20230183256-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSME3, PSMC4 | HSD11B1 2082/4885POLB 1022/4885ALDH1A1 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.